

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A ~~pharmaceutical composition for treating a solid tumor, or metastasis thereof, said composition~~ comprising a gene carrier for expression in human or animal cells, or *ex vivo* cells, harboring a [[gene]] nucleic acid molecule encoding a recombinant protein consisting of human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) as an effective ingredient.

2. (Currently amended) The composition according to claim 1, wherein the LK68 [[gene]] encoding molecule comprises a nucleotide sequence represented by SEQ. ID. No. 1.

3. (Currently amended) The composition according to claim 1, wherein the gene carrier harboring the LK68 [[gene]] encoding molecule is a vector or a recombinant virus.

4. (Previously presented) The composition according to claim 3, wherein the vector is selected from a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

5. (Previously presented) The composition according to claim 3, wherein the recombinant virus is selected from retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

6. (Previously presented) The composition according to claim 1, wherein the cells are selected from hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells.

7. (Previously presented) The composition according to claim 1, wherein the gene carrier is selected from pSecTag-LK68, pLXSN-LK68, rAAV-LK68 and pAAV-LK68.

8. (Currently amended) The composition according to claim 1, wherein the LK8 [[gene]] encoding molecule comprises a nucleotide sequence represented by SEQ. ID. No. 2.

9. (Previously presented) The composition according to claim 1, wherein the gene carrier harboring the LK8 gene is a vector or a recombinant virus.

10. (Previously presented) The composition according to claim 9, wherein the vector is selected from a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

11. (Previously presented) The composition according to claim 9, wherein the recombinant virus is selected from retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

12. (Previously presented) The composition according to claim 9, wherein the gene carrier is selected from pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

13. (Previously presented) The composition according to claim 3, wherein the vector is included by 0.05 ~ 500 mg.

14. (Previously presented) The composition according to claim 3, wherein the recombinant virus is included by 10^3 - 10^{12} IU.

15. (Previously presented) The composition according to claim 1, wherein the cells are included by 10^3 - 10^8 e.a.

16. (Previously presented) The composition according to claim 1, wherein the solid tumor is selected from colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. (Previously presented) The composition according to claim 16, wherein the solid tumor is selected from colon carcinoma, liver cancer, lymphoma and metastatic tumor.

18. (Currently amended) A method for ~~prevention or treatment of~~ preventing or treating a solid tumor, which ~~includes a step of~~ method comprises parenteral administration of ~~the composition of claim 1~~ a gene carrier, or *ex vivo* cells, harboring a nucleic acid molecule encoding a recombinant human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) to an individual, wherein said gene carrier or cells express said molecule to prevent or treat said solid tumor.

19. (Previously presented) The method according to claim 18, wherein the prevention or the treatment of a solid tumor is accomplished by inhibition of growth and metastasis of the solid tumor.

20. (Currently amended) The method according to claim 18, wherein the administration of a gene carrier harboring human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) ~~[[gene]]~~ encoding molecule is accomplished by a method selected from chemical method, physical method, conjugation using liposome, a method using receptor and virus.

21. (Currently amended) The method according to claim 18, wherein the administration is characterized by injecting cells selected from hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells transfected with human apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or KV(LK8) ~~[[gene]]~~ encoding molecule to a patient.

22. (Previously presented) The composition according to claim 9, wherein the vector is included by 0.05 ~ 500 mg.

23. (Previously presented) The composition according to claim 9, wherein the recombinant virus is included by 10^3 - 10^{12} IU.